BACKGROUND: Observational studies suggest an inverse association between selenium and risk of prostate cancer. However, randomized controlled trials of selenium supplementation have reported conflicting results. Thus, we examined plasma selenium and selenium-related genes in relation to risk of high-grade prostate cancer and prostate cancer recurrence among men initially diagnosed with non-metastatic disease. METHODS: We measured plasma selenium and genotyped 73 single nucleotide polymorphisms in TXNRD1, TXNRD2, GPX1, GPX3, GPX4, SEP15, SEPP1, SELENBP1, OGG1, and CAT among 568 men with non-metastatic prostate cancer who underwent radical prostatectomy. We examined associations between plasma selenium, genotypes, and risk of high-grade prostate cancer (Gleason grade ≥8 or 7 with primary score ≥4; n = 111) using logistic regression, and risk of prostate cancer recurrence (61 events; 3.8 y median follow-up) using Cox proportional hazards regression. RESULTS: Plasma selenium was not associated with risk of high-grade prostate cancer or prostate cancer recurrence. Less common alleles of rs11913319 in TXNRD2 and rs125701 in OGG1 were associated with an increased risk of high-grade prostate cancer. We observed associations between the risk of prostate cancer recurrence and multiple SNPs in TXNRD1, TXNRD2, GPX3, and SEP15. These associations were no longer statistically significant after adjustment for multiple comparisons. CONCLUSIONS: Among men with non-metastatic prostate cancer, there is suggestive evidence that genetic variation in selenoproteins and related antioxidant enzymes may be associated with risk of high-grade disease at diagnosis and prostate cancer recurrence.
BACKGROUND: Observational studies suggest an inverse association between selenium and risk of prostate cancer. However, randomized controlled trials of selenium supplementation have reported conflicting results. Thus, we examined plasma selenium and selenium-related genes in relation to risk of high-grade prostate cancer and prostate cancer recurrence among men initially diagnosed with non-metastatic disease. METHODS: We measured plasma selenium and genotyped 73 single nucleotide polymorphisms in TXNRD1, TXNRD2, GPX1, GPX3, GPX4, SEP15, SEPP1, SELENBP1, OGG1, and CAT among 568 men with non-metastatic prostate cancer who underwent radical prostatectomy. We examined associations between plasma selenium, genotypes, and risk of high-grade prostate cancer (Gleason grade ≥8 or 7 with primary score ≥4; n = 111) using logistic regression, and risk of prostate cancer recurrence (61 events; 3.8 y median follow-up) using Cox proportional hazards regression. RESULTS: Plasma selenium was not associated with risk of high-grade prostate cancer or prostate cancer recurrence. Less common alleles of rs11913319 in TXNRD2 and rs125701 in OGG1 were associated with an increased risk of high-grade prostate cancer. We observed associations between the risk of prostate cancer recurrence and multiple SNPs in TXNRD1, TXNRD2, GPX3, and SEP15. These associations were no longer statistically significant after adjustment for multiple comparisons. CONCLUSIONS: Among men with non-metastatic prostate cancer, there is suggestive evidence that genetic variation in selenoproteins and related antioxidant enzymes may be associated with risk of high-grade disease at diagnosis and prostate cancer recurrence.
Authors: Rachel Hurst; Lee Hooper; Teresa Norat; Rosa Lau; Dagfinn Aune; Darren C Greenwood; Rui Vieira; Rachel Collings; Linda J Harvey; Jonathan A C Sterne; Rebecca Beynon; Jelena Savović; Susan J Fairweather-Tait Journal: Am J Clin Nutr Date: 2012-05-30 Impact factor: 7.045
Authors: Milan S Geybels; Carolyn M Hutter; Erika M Kwon; Elaine A Ostrander; Rong Fu; Ziding Feng; Janet L Stanford; Ulrike Peters Journal: Prostate Date: 2012-11-09 Impact factor: 4.104
Authors: Matthew L Cooper; Hans-Olov Adami; Henrik Grönberg; Fredrik Wiklund; Fiona R Green; Margaret P Rayman Journal: Cancer Res Date: 2008-12-15 Impact factor: 12.701
Authors: Zorica Arsova-Sarafinovska; Nadica Matevska; Ayse Eken; Daniel Petrovski; Saso Banev; Sonja Dzikova; Vladimir Georgiev; Aleksandar Sikole; Onur Erdem; Ahmet Sayal; Ahmet Aydin; Aleksandar J Dimovski Journal: Int Urol Nephrol Date: 2008-06-19 Impact factor: 2.370
Authors: Scott M Lippman; Eric A Klein; Phyllis J Goodman; M Scott Lucia; Ian M Thompson; Leslie G Ford; Howard L Parnes; Lori M Minasian; J Michael Gaziano; Jo Ann Hartline; J Kellogg Parsons; James D Bearden; E David Crawford; Gary E Goodman; Jaime Claudio; Eric Winquist; Elise D Cook; Daniel D Karp; Philip Walther; Michael M Lieber; Alan R Kristal; Amy K Darke; Kathryn B Arnold; Patricia A Ganz; Regina M Santella; Demetrius Albanes; Philip R Taylor; Jeffrey L Probstfield; T J Jagpal; John J Crowley; Frank L Meyskens; Laurence H Baker; Charles A Coltman Journal: JAMA Date: 2008-12-09 Impact factor: 56.272
Authors: Philip W Kantoff; Lorelei A Mucci; June M Chan; Amy K Darke; Kathryn L Penney; Catherine M Tangen; Phyllis J Goodman; Gwo-Shu Mary Lee; Tong Sun; Sam Peisch; Alex M Tinianow; James M Rae; Eric A Klein; Ian M Thompson Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-05-06 Impact factor: 4.254
Authors: Wanling Xie; Ming Yang; June Chan; Tong Sun; Lorelei A Mucci; Kathryn L Penney; Gwo-Shu Mary Lee; Philip W Kantoff Journal: Prostate Date: 2016-02-05 Impact factor: 4.104
Authors: Tobias Nordström; Erin L Van Blarigan; Vy Ngo; Ritu Roy; Vivian Weinberg; Xiaoling Song; Jeffry Simko; Peter R Carroll; June M Chan; Pamela L Paris Journal: Prostate Date: 2015-11-20 Impact factor: 4.104
Authors: Naomi E Allen; Ruth C Travis; Paul N Appleby; Demetrius Albanes; Matt J Barnett; Amanda Black; H Bas Bueno-de-Mesquita; Mélanie Deschasaux; Pilar Galan; Gary E Goodman; Phyllis J Goodman; Marc J Gunter; Markku Heliövaara; Kathy J Helzlsouer; Brian E Henderson; Serge Hercberg; Paul Knekt; Laurence N Kolonel; Christina Lasheras; Jakob Linseisen; E Jeffrey Metter; Marian L Neuhouser; Anja Olsen; Valeria Pala; Elizabeth A Platz; Harri Rissanen; Mary E Reid; Jeannette M Schenk; Meir J Stampfer; Pär Stattin; Catherine M Tangen; Mathilde Touvier; Antonia Trichopoulou; Piet A van den Brandt; Timothy J Key Journal: J Natl Cancer Inst Date: 2016-07-06 Impact factor: 13.506